Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.
about
The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future ResearchMetabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.Weight gain, obesity, and psychotropic prescribing.The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.Atypical antipsychotics and diabetes mellitus.Use of olanzapine in the treatment of bipolar I disorder.Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.Drug-induced hyperphagia: what can we learn from psychiatric medications?Sex-specific differences in side effects of psychotropic drugs: genes or gender?Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Obesity and psychotropics.Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia.Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.Weight gain in a patient with schizophrenia switched from quetiapine to amisulpride.Antipsychotic drug-induced weight gain: development of an animal model.Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs.Quality of life issues associated with antipsychotic-induced weight gain.Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study.Switching patients to atypical oral antipsychotics: A retrospective audit of depot clinic attenders
P2860
Q28072601-32954482-31A6-4A24-985D-8042559202A3Q34037969-C999CC27-B831-41CD-BC69-BDA17FB8A90FQ34557537-D3B7550D-4CB4-45F7-A85C-E53B64430628Q35752734-251F3C30-6BC5-4B16-B89D-7C4BBF1D4879Q35793345-B3AC7A26-DDB2-45CC-87B3-6A0EBB0B54DAQ36106843-3BA56241-C052-4EE6-AB91-D4D10741B517Q36178681-F3C20FF1-38FE-4750-8D73-57F3F0A8E43FQ36720733-2DAD4423-B0A9-4454-97D7-9680DAFFD335Q37210118-265C4E4C-C489-4FA2-AC0B-A98E79D01E63Q37254782-716CA669-E440-4D40-AFDF-E0E18BA94229Q37598900-F31F6F73-F0BC-4019-8B4E-8819C1DE3E79Q37865505-41E9234C-EA18-4B15-AEB1-BB12EB405AAEQ37926893-CFA25C1F-618A-4C80-972A-715242CCFAD9Q37954390-F61EE083-D8DF-48B6-8AFF-E8F8020D7835Q38050714-837CBEC8-90D8-4229-9C90-7F9B3DEBB49AQ41066568-19D7DBAA-2182-4367-85F7-98E45F71CF5FQ43228766-9B915DB4-64DE-43FD-8587-D5CC271CA601Q43294341-D07CD065-046D-4340-888C-23AC038AC59BQ45052998-12D818C0-B1B7-451B-BD92-09B60D67AD2EQ46117105-E6B2C53C-E7DE-4430-BCA6-1AF314B9A518Q46298105-4D1E6D59-E416-4EB6-80D1-758FFD75A6DAQ46408562-C6D8F58C-B637-4326-90CF-8CEDE0D2AEC5Q46902584-49D37832-D092-47F6-B472-CD90DC35330FQ47228167-A798B914-A99B-4B15-B2D8-F4F5EC7854CEQ47441133-E916A779-C55E-4BAF-B390-B81DD590E138Q47788036-4DC5A26E-6E9D-4A49-97C9-AA541B8B604CQ58192675-D3B4E856-FE48-407F-BAAA-1D0A8DE447F2
P2860
Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Bodyweight gain associated wit ...... and therapeutic implications.
@ast
Bodyweight gain associated wit ...... and therapeutic implications.
@en
Bodyweight gain associated wit ...... and therapeutic implications.
@nl
type
label
Bodyweight gain associated wit ...... and therapeutic implications.
@ast
Bodyweight gain associated wit ...... and therapeutic implications.
@en
Bodyweight gain associated wit ...... and therapeutic implications.
@nl
prefLabel
Bodyweight gain associated wit ...... and therapeutic implications.
@ast
Bodyweight gain associated wit ...... and therapeutic implications.
@en
Bodyweight gain associated wit ...... and therapeutic implications.
@nl
P1433
P1476
Bodyweight gain associated wit ...... and therapeutic implications.
@en
P2093
Mackell JA
Russell JM
P304
P356
10.2165/00023210-200115070-00004
P577
2001-01-01T00:00:00Z
P6179
1009279304